Your browser doesn't support javascript.
loading
Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF.
Ferreira, João Pedro; Verdonschot, Job; Wang, Ping; Pizard, Anne; Collier, Timothy; Ahmed, Fozia Z; Brunner-La-Rocca, Hans-Peter; Clark, Andrew L; Cosmi, Franco; Cuthbert, Joe; Díez, Javier; Edelmann, Frank; Girerd, Nicolas; González, Arantxa; Grojean, Stéphanie; Hazebroek, Mark; Khan, Javed; Latini, Roberto; Mamas, Mamas A; Mariottoni, Beatrice; Mujaj, Blerim; Pellicori, Pierpaolo; Petutschnigg, Johannes; Pieske, Burkert; Rossignol, Patrick; Rouet, Philippe; Staessen, Jan A; Cleland, John G F; Heymans, Stephane; Zannad, Faiez.
Afiliação
  • Ferreira JP; Université de Lorraine, Inserm, Centre d'Investigation Clinique Plurithématique 1433, CHRU de Nancy, F-CRIN INI-CRCT, Nancy, France. Electronic address: j.ferreira@chru-nancy.fr.
  • Verdonschot J; Department of Cardiology, Maastricht University Medical Center, the Netherlands.
  • Wang P; Department of Cardiology, Maastricht University Medical Center, the Netherlands.
  • Pizard A; Université de Lorraine, Inserm, Centre d'Investigation Clinique Plurithématique 1433, CHRU de Nancy, F-CRIN INI-CRCT, Nancy, France.
  • Collier T; Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, United Kingdom.
  • Ahmed FZ; Division of Cardiovascular Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom.
  • Brunner-La-Rocca HP; Department of Cardiology, Maastricht University Medical Center, the Netherlands.
  • Clark AL; Department of Academic Cardiology, University of Hull, Castle Hill Hospital, Cottingham, United Kingdom.
  • Cosmi F; Department of Cardiology, Cortona Hospital, Arezzo, Italy.
  • Cuthbert J; Department of Academic Cardiology, University of Hull, Castle Hill Hospital, Cottingham, United Kingdom.
  • Díez J; Program of Cardiovascular Diseases, CIMA Universidad de Navarra and IdiSNA, Pamplona, Spain; CIBERCV, Carlos III Institute of Health, Madrid, Spain.
  • Edelmann F; Department of Internal Medicine/Cardiology, German Heart Center Berlin, Berlin, Germany.
  • Girerd N; Robertson Centre for Biostatistics, Institute of Health and Wellbeing, University of Glasgow, Glasgow Royal Infirmary, Glasgow, United Kingdom.
  • González A; Program of Cardiovascular Diseases, CIMA Universidad de Navarra and IdiSNA, Pamplona, Spain; CIBERCV, Carlos III Institute of Health, Madrid, Spain.
  • Grojean S; Université de Lorraine, Inserm, Centre d'Investigation Clinique Plurithématique 1433, CHRU de Nancy, F-CRIN INI-CRCT, Nancy, France.
  • Hazebroek M; Department of Cardiology, Maastricht University Medical Center, the Netherlands.
  • Khan J; Robertson Centre for Biostatistics, Institute of Health and Wellbeing, University of Glasgow, Glasgow Royal Infirmary, Glasgow, United Kingdom.
  • Latini R; Mario Negri Institute of Pharmacological Research-IRCCS, Milan, Italy.
  • Mamas MA; Division of Cardiovascular Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom.
  • Mariottoni B; Department of Cardiology, Cortona Hospital, Arezzo, Italy.
  • Mujaj B; Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium.
  • Pellicori P; Robertson Centre for Biostatistics, Institute of Health and Wellbeing, University of Glasgow, Glasgow Royal Infirmary, Glasgow, United Kingdom.
  • Petutschnigg J; Department of Internal Medicine/Cardiology, German Heart Center Berlin, Berlin, Germany.
  • Pieske B; Department of Internal Medicine/Cardiology, German Heart Center Berlin, Berlin, Germany.
  • Rossignol P; Université de Lorraine, Inserm, Centre d'Investigation Clinique Plurithématique 1433, CHRU de Nancy, F-CRIN INI-CRCT, Nancy, France.
  • Rouet P; UMR UT3 CNRS 5288, Obesity and Heart Failure, Toulouse, France.
  • Staessen JA; Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium.
  • Cleland JGF; Robertson Centre for Biostatistics, Institute of Health and Wellbeing, University of Glasgow, Glasgow Royal Infirmary, Glasgow, United Kingdom.
  • Heymans S; Department of Cardiology, Maastricht University Medical Center, the Netherlands.
  • Zannad F; Université de Lorraine, Inserm, Centre d'Investigation Clinique Plurithématique 1433, CHRU de Nancy, F-CRIN INI-CRCT, Nancy, France. Electronic address: f.zannad@chru-nancy.fr.
JACC Heart Fail ; 9(4): 268-277, 2021 04.
Article em En | MEDLINE | ID: mdl-33549556
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Espironolactona / Insuficiência Cardíaca Tipo de estudo: Clinical_trials / Etiology_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male Idioma: En Revista: JACC Heart Fail Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Espironolactona / Insuficiência Cardíaca Tipo de estudo: Clinical_trials / Etiology_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male Idioma: En Revista: JACC Heart Fail Ano de publicação: 2021 Tipo de documento: Article